STAT+: Amgen’s Repatha linked to fewer heart attacks

Novartis cites more tumor reports, PhRMA’s big spending on search ads, and more biotech news Alex Hogan/ STAT Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Pithy intro text about the biopharma milieu. Novartis cites more tumor reports after Zolgensma Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, its gene therapy for spinal muscular atrophy. The company has received nine tumor reports in all since the treatment was approved in 2019, STAT’s Ed Silverman and Jason Mast write. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Meghana Keshavan covers biotech and contributes to The Readout newsletter.